{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:40:38Z","timestamp":1790052038511,"version":"4.0.1"},"reference-count":95,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,1]]},"DOI":"10.1210\/endo.143.6.8890","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T16:12:02Z","timestamp":1389197522000},"page":"2029-2040","source":"Crossref","is-referenced-by-count":35,"title":["Perspective: Prostate Cancer Susceptibility Genes"],"prefix":"10.1210","volume":"143","author":[{"given":"Jacques","family":"Simard","sequence":"first","affiliation":[{"name":"Canada Research Chair in Oncogenetics (J.S., M.D., P.S.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"},{"name":"Oncology and Molecular Endocrinology Research Center (J.S., M.D., P.S., F.L.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Dumont","sequence":"additional","affiliation":[{"name":"Canada Research Chair in Oncogenetics (J.S., M.D., P.S.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"},{"name":"Oncology and Molecular Endocrinology Research Center (J.S., M.D., P.S., F.L.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Soucy","sequence":"additional","affiliation":[{"name":"Canada Research Chair in Oncogenetics (J.S., M.D., P.S.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"},{"name":"Oncology and Molecular Endocrinology Research Center (J.S., M.D., P.S., F.L.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Labrie","sequence":"additional","affiliation":[{"name":"Oncology and Molecular Endocrinology Research Center (J.S., M.D., P.S., F.L.), CHUL Research Center and Laval University, Que\u0301bec City, G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041121244022200_R1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B","article-title":"International trends and patterns of prostate cancer incidence and mortality.","volume":"85","author":"Hsing","year":"2000","journal-title":"Int J Cancer"},{"key":"2019041121244022200_R2","doi-asserted-by":"crossref","unstructured":"Labrie F, Cancer of the prostate. In: Pollock R, ed. The UICC manual of clinical oncology, 8th ed., in press","DOI":"10.1016\/S0140-6736(94)92747-2"},{"key":"2019041121244022200_R3","first-page":"304","article-title":"Recherches clinico-statistiques et ge\u0301ne\u0301tiques sur les ne\u0301oplasies de la prostate.","volume":"6","author":"Morganti","year":"1956","journal-title":"Acta Genet"},{"key":"2019041121244022200_R4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.pcan.4500279","article-title":"The UK Familial Prostate Study Co-ordinating Group & The CRC\/BPG UK Familial Prostate Study Collaborators.","volume":"2","author":"Eeles","year":"1999","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2019041121244022200_R5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1086\/316916","article-title":"Genetics of prostate cancer: too many loci, too few genes.","volume":"67","author":"Ostrander","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.pcan.4500478","article-title":"High risk genes predisposing to prostate cancer\u2014do they exist?","volume":"3","author":"Singh R","year":"2000","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2019041121244022200_R7","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/hmg\/10.20.2313","article-title":"Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease.","volume":"10","author":"Nwosu","year":"2001","journal-title":"Hum Mol Genet"},{"key":"2019041121244022200_R8","first-page":"320","author":"Eeles","year":"1996"},{"key":"2019041121244022200_R9","first-page":"47","article-title":"Genetic epidemiology of prostate cancer in the Utah Mormon genealogy.","volume":"1","author":"Cannon","year":"1982","journal-title":"Cancer Surv"},{"key":"2019041121244022200_R10","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1073\/pnas.89.8.3367","article-title":"Mendelian inheritance of familial prostate cancer.","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041121244022200_R11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.2990170409","article-title":"Family history and the risk of prostate cancer.","volume":"17","author":"Steinberg","year":"1990","journal-title":"Prostate"},{"key":"2019041121244022200_R12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer\u2014 analyses of cohorts of twins from Sweden, Denmark, and Finland.","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"key":"2019041121244022200_R13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/301862","article-title":"Evidence for autosomal dominant inheritance of prostate cancer.","volume":"62","author":"Schaid","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.1997.03550150055035","article-title":"Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus.","volume":"278","author":"Gronberg","year":"1997","journal-title":"JAMA"},{"key":"2019041121244022200_R15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm0295-99","article-title":"The impact of family history on early detection of prostate cancer.","volume":"1","author":"Narod","year":"1995","journal-title":"Nat Med"},{"key":"2019041121244022200_R16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0895-827","article-title":"Evidence of an X-linked or recessive genetic component to prostate cancer risk.","volume":"1","author":"Monroe","year":"1995","journal-title":"Nat Med"},{"key":"2019041121244022200_R17","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1126\/science.274.5291.1371","article-title":"Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search.","volume":"274","author":"Smith","year":"1996","journal-title":"Science"},{"key":"2019041121244022200_R18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s004390100488","article-title":"Linkage of prostate cancer susceptibility loci to chromosome 1.","volume":"108","author":"Xu","year":"2001","journal-title":"Hum Genet"},{"key":"2019041121244022200_R19","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1086\/301879","article-title":"Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2\u201343.","volume":"62","author":"Berthon","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/2477","article-title":"Evidence for a prostate cancer susceptibility locus on the X chromosome.","volume":"20","author":"Xu","year":"1998","journal-title":"Nat Genet"},{"key":"2019041121244022200_R21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1086\/302287","article-title":"Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.","volume":"64","author":"Gibbs","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/302994","article-title":"Evidence for a prostate cancer-susceptibility locus on chromosome 20.","volume":"67","author":"Berry","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/84808","article-title":"A candidate prostate cancer susceptibility gene at chromosome 17p.","volume":"27","author":"Tavtigian","year":"2001","journal-title":"Nat Genet"},{"key":"2019041121244022200_R24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1086\/321967","article-title":"Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22\u201323.","volume":"69","author":"Xu","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R25","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1101\/gad.819500","article-title":"Molecular genetics of prostate cancer.","volume":"14","author":"Abate-Shen","year":"2000","journal-title":"Genes Dev"},{"key":"2019041121244022200_R26","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/hmg\/8.13.2437","article-title":"Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees.","volume":"8","author":"Neuhausen","year":"1999","journal-title":"Hum Mol Genet"},{"key":"2019041121244022200_R27","first-page":"945","article-title":"International Consortium for Prostate Cancer Genetics.","volume":"66","author":"Xu","year":"2000","journal-title":"Combined analysis of hereditary prostate cancer linkage to 1q24\u201325: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics (published erratum appears in Am J Hum Genet 2000;67:541\u2013542)"},{"key":"2019041121244022200_R28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/301745","article-title":"Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign\/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators.","volume":"62","author":"Eeles","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1098-2272(200003)18:3<251::AID-GEPI5>3.0.CO;2-X","article-title":"Linkage analysis of 150 high-risk prostate cancer families at 1q24\u201325.","volume":"18","author":"Goode","year":"2000","journal-title":"Genet Epidemiol"},{"key":"2019041121244022200_R30","first-page":"4810","article-title":"A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease.","volume":"6","author":"Schleutker","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2019041121244022200_R31","first-page":"2739","article-title":"Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci.","volume":"7","author":"Goode","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2019041121244022200_R32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.ejhg.5200592","article-title":"PCAP is the major known prostate cancer predisposing locus in families from south and west Europe.","volume":"9","author":"Cancel-Tassin","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"2019041121244022200_R33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1086\/320103","article-title":"Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4.","volume":"68","author":"Goddard","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/302771","article-title":"Linkage analyses at the chromosome 1 loci 1q24\u201325 (HPC1), 1q42.2\u201343 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer.","volume":"66","author":"Berry","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/jmg.37.12.947","article-title":"Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC\/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators.","volume":"37","author":"Badzioch","year":"2000","journal-title":"J Med Genet"},{"key":"2019041121244022200_R36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s004390100513","article-title":"Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families.","volume":"108","author":"Zheng","year":"2001","journal-title":"Hum Genet"},{"key":"2019041121244022200_R37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1086\/318797","article-title":"Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer.","volume":"68","author":"Bock","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R38","first-page":"4013","article-title":"Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX.","volume":"5","author":"Lange","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2019041121244022200_R39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000022965","article-title":"Genetic linkage analysis of prostate cancer families to Xq27\u201328.","volume":"51","author":"Peters","year":"2001","journal-title":"Hum Hered"},{"key":"2019041121244022200_R40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s004390000384","article-title":"Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer.","volume":"107","author":"Bergthorsson","year":"2000","journal-title":"Hum Genet"},{"key":"2019041121244022200_R41","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1126\/science.1439824","article-title":"Assignment of a locus for familial melanoma, MLM, to chromosome 9p13- p22.","volume":"258","author":"Cannon-Albright","year":"1992","journal-title":"Science"},{"key":"2019041121244022200_R42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"2019041121244022200_R43","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12\u201313.","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"2019041121244022200_R44","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/303096","article-title":"Association of HPC2\/ELAC2 genotypes and prostate cancer.","volume":"67","author":"Rebbeck","year":"2000","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R45","first-page":"4982","article-title":"Polymorphisms in the prostate cancer susceptibility gene HPC2\/ELAC2 in multiplex families and healthy controls.","volume":"61","author":"Suarez","year":"2001","journal-title":"Cancer Res"},{"key":"2019041121244022200_R46","first-page":"6494","article-title":"Role of HPC2\/ELAC2 in hereditary prostate cancer.","volume":"61","author":"Wang","year":"2001","journal-title":"Cancer Res"},{"key":"2019041121244022200_R47","first-page":"6038","article-title":"ELAC2\/HPC2 involvement in hereditary and sporadic prostate cancer.","volume":"61","author":"Rokman","year":"2001","journal-title":"Cancer Res"},{"key":"2019041121244022200_R48","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1086\/319513","article-title":"Evaluation of linkage and association of HPC2\/ELAC2 in patients with familial or sporadic prostate cancer.","volume":"68","author":"Xu","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng823","article-title":"Germline mutations in the ribonuclease L gene in families showing linkage with HPC1.","volume":"30","author":"Carpten","year":"2002","journal-title":"Nat Genet"},{"key":"2019041121244022200_R50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jnci\/84.14.1114","article-title":"Breast cancer risks in relatives of male breast cancer patients.","volume":"84","author":"Anderson","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"2019041121244022200_R51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bmj.305.6858.855","article-title":"Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer.","volume":"305","author":"Tulinius","year":"1992","journal-title":"Br Med J"},{"key":"2019041121244022200_R52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"2019041121244022200_R53","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","journal-title":"J Natl Cancer Inst"},{"key":"2019041121244022200_R54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng0596-117","article-title":"A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.","volume":"13","author":"Thorlacius","year":"1996","journal-title":"Nat Genet"},{"key":"2019041121244022200_R55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s001090050162","article-title":"BRCA2 mutation in Icelandic prostate cancer patients.","volume":"75","author":"Sigurdsson","year":"1997","journal-title":"J Mol Med"},{"key":"2019041121244022200_R56","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(98)03300-5","article-title":"Population-based study of risk of breast cancer in carriers of BRCA2 mutation.","volume":"352","author":"Thorlacius","year":"1998","journal-title":"Lancet"},{"key":"2019041121244022200_R57","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bjc.1998.576","article-title":"Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.","volume":"78","author":"Lehrer","year":"1998","journal-title":"Br J Cancer"},{"key":"2019041121244022200_R58","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1086\/302525","article-title":"The Jewish Ashkenazi founder mutations in the BRCA1\/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.","volume":"65","author":"Hubert","year":"1999","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F","article-title":"No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer.","volume":"39","author":"Wilkens","year":"1999","journal-title":"Prostate"},{"key":"2019041121244022200_R60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0045(19990801)40:3<172::AID-PROS5>3.0.CO;2-R","article-title":"Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.","volume":"40","author":"Nastiuk","year":"1999","journal-title":"Prostate"},{"key":"2019041121244022200_R61","first-page":"4513","article-title":"The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign\/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.","volume":"60","author":"Gayther","year":"2000","journal-title":"Cancer Res"},{"key":"2019041121244022200_R62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1090>3.0.CO;2-U","article-title":"BRCA2 mutation in a family with hereditary prostate cancer.","volume":"30","author":"Gronberg","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"2019041121244022200_R63","first-page":"1371","article-title":"BRCA1 and BRCA2 have a limited role in familial prostate cancer.","volume":"60","author":"Sinclair","year":"2000","journal-title":"Cancer Res"},{"key":"2019041121244022200_R64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000019909","article-title":"Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility.","volume":"35","author":"Ross","year":"1999","journal-title":"Eur Urol"},{"key":"2019041121244022200_R65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/oxfordjournals.epirev.a000791","article-title":"Molecular epidemiology of hormone-metabolic loci in prostate cancer.","volume":"23","author":"Makridakis","year":"2001","journal-title":"Epidemiol Rev"},{"key":"2019041121244022200_R66","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y","article-title":"The androgen receptor gene and its influence on the development and progression of prostate cancer.","volume":"195","author":"Montgomery","year":"2001","journal-title":"J Pathol"},{"key":"2019041121244022200_R67","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/jnci\/93.22.1687","article-title":"Androgen receptor signaling in androgen-refractory prostate cancer.","volume":"93","author":"Grossmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2019041121244022200_R68","first-page":"423","article-title":"Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.","volume":"61","author":"Henshall","year":"2001","journal-title":"Cancer Res"},{"key":"2019041121244022200_R69","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res"},{"key":"2019041121244022200_R70","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/nar\/22.15.3181","article-title":"The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.","volume":"22","author":"Chamberlain","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"2019041121244022200_R71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/hmg\/4.4.523","article-title":"Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies.","volume":"4","author":"Kazemi-Esfarjani","year":"1995","journal-title":"Hum Mol Genet"},{"key":"2019041121244022200_R72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1677\/jme.0.0250085","article-title":"Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines.","volume":"25","author":"Beilin","year":"2000","journal-title":"J Mol Endocrinol"},{"key":"2019041121244022200_R73","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.1098","article-title":"Polymorphic repeats in the androgen receptor gene in high-risk sibships.","volume":"48","author":"Miller","year":"2001","journal-title":"Prostate"},{"key":"2019041121244022200_R74","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000134362","article-title":"Genetic linkage mapping of the human steroid 5\u03b1-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23->p22.","volume":"73","author":"Morissette","year":"1996","journal-title":"Cytogenet Cell Genet"},{"key":"2019041121244022200_R75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0039-128X(98)00007-5","article-title":"DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging.","volume":"63","author":"Labrie","year":"1998","journal-title":"Steroids"},{"key":"2019041121244022200_R76","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0140-6736(92)90927-U","article-title":"5\u03b1-Reductase activity and risk of prostate cancer among Japanese and US white and black males.","volume":"339","author":"Ross","year":"1992","journal-title":"Lancet"},{"key":"2019041121244022200_R77","first-page":"3973","article-title":"Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.","volume":"55","author":"Reichardt","year":"1995","journal-title":"Cancer Res"},{"key":"2019041121244022200_R78","first-page":"1020","article-title":"A prevalent missense substitution that modulates activity of prostatic steroid 5\u03b1-reductase.","volume":"57","author":"Makridakis","year":"1997","journal-title":"Cancer Res"},{"key":"2019041121244022200_R79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00008571-200007000-00004","article-title":"Biochemical and pharmacogenetic dissection of human steroid 5\u03b1-reductase type II.","volume":"10","author":"Makridakis","year":"2000","journal-title":"Pharmacogenetics"},{"key":"2019041121244022200_R80","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(98)11282-5","article-title":"Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.","volume":"354","author":"Makridakis","year":"1999","journal-title":"Lancet"},{"key":"2019041121244022200_R81","first-page":"1626","article-title":"Association of SRD5A2 genotype and pathological characteristics of prostate tumors.","volume":"60","author":"Jaffe","year":"2000","journal-title":"Cancer Res"},{"key":"2019041121244022200_R82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1155\/2000\/683607","article-title":"Evidence for an association between the SRD5A2 (type II steroid 5\u03b1- reductase) locus and prostate cancer in Italian patients.","volume":"16","author":"Margiotti","year":"2000","journal-title":"Dis Markers"},{"key":"2019041121244022200_R83","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.2001.1789","article-title":"A missense substitution A49T in the steroid 5\u03b1-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.","volume":"84","author":"Mononen","year":"2001","journal-title":"Br J Cancer"},{"key":"2019041121244022200_R84","first-page":"1077","article-title":"Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.","volume":"10","author":"Hsing","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2019041121244022200_R85","first-page":"2825","article-title":"CYP17 and breast cancer risk: the polymorphism in the 5\u2032 flanking area of the gene does not influence binding to Sp-1.","volume":"59","author":"Nedelcheva Kristensen","year":"1999","journal-title":"Cancer Res"},{"key":"2019041121244022200_R86","unstructured":"Lin C, Miller, WL, The T\/C allelic polymorphism at nucleotide +27 of the human CYP17 gene is not associated with altered transcriptional activity. Program of The 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 295 (Abstract P2-1)"},{"key":"2019041121244022200_R87","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/carcin\/20.9.1727","article-title":"Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).","volume":"20","author":"Lunn","year":"1999","journal-title":"Carcinogenesis"},{"key":"2019041121244022200_R88","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/1097-0215(20000801)87:3<434::AID-IJC19>3.0.CO;2-G","article-title":"A polymorphism in the CYP17 gene is associated with prostate cancer risk.","volume":"87","author":"Gsur","year":"2000","journal-title":"Int J Cancer"},{"key":"2019041121244022200_R89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4","article-title":"Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5\u03b1-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.","volume":"92","author":"Yamada","year":"2001","journal-title":"Int J Cancer"},{"key":"2019041121244022200_R90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-199910000-00010","article-title":"Prostate cancer associated with CYP17 genotype.","volume":"9","author":"Wadelius","year":"1999","journal-title":"Pharmacogenetics"},{"key":"2019041121244022200_R91","first-page":"5710","article-title":"Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.","volume":"60","author":"Habuchi","year":"2000","journal-title":"Cancer Res"},{"key":"2019041121244022200_R92","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1097-0215(20011120)95:6<354::AID-IJC1062>3.0.CO;2-3","article-title":"Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer.","volume":"95","author":"Chang","year":"2001","journal-title":"Int J Cancer"},{"key":"2019041121244022200_R93","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1086\/320102","article-title":"Regression models for linkage heterogeneity applied to familial prostate cancer.","volume":"68","author":"Schaid","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041121244022200_R94","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer.","volume":"415","author":"Veer","year":"2002","journal-title":"Nature"},{"key":"2019041121244022200_R95","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0092-8674(01)00574-8","article-title":"Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes.","volume":"107","author":"Blackshaw","year":"2001","journal-title":"Cell"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/143\/6\/2029\/10367845\/endo2029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:58:14Z","timestamp":1555059494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/143\/6\/2029\/2989354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,1]]},"references-count":95,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endo.143.6.8890","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,1]]}}}